Interaction Checker

About Us
Mission Statement Meet the Team Steering Committee
Interaction Checkers
Interaction Checker View All Checker
Prescribing Resources Site News Contact Us

No Interaction Expected

COVID-19 vaccines

Abacavir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Abatacept

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Abemaciclib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Abiraterone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Abrocitinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Acalabrutinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Acarbose

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Acenocoumarol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Acetazolamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Acetylcysteine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Aciclovir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Acitretin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Aclidinium bromide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Adalimumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Adefovir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Adrenaline (Epinephrine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Afatinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

African Potato

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Agomelatine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Albuvirtide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Alcohol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Alcuronium

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Aldesleukin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Alectinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Alemtuzumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. The ability to generate an immune response with COVID-19 vaccines under alemtuzumab treatment has not been studied However, a small study in patients with multiple sclerosis on anti-CD20 treatment suggest that COVID-19 vaccines may still provoke an appropriate immune response in those patients.

Description:

B cell and T cell responses to mRNA COVID-19 vaccination were studied in 20 patients taking anti-CD20 therapy for multiple sclerosis. A competent vaccine-induced CD8 T cell response was seen in these patients.
Sokratis A Apostolidis, Mihir Kakara, Mark M Painter et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy, Nature Medicine, 2021, 27:1990-2001.

No Interaction Expected

COVID-19 vaccines

Alendronic acid (Alendronate)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Alfentanil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Alfuzosin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Alirocumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Aliskiren

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Allopurinol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Almotriptan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Alogliptin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Alosetron

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Alpelisib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Alprazolam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Amantadine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ambrisentan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Amikacin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Amiloride

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Aminophylline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Amiodarone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Amisulpride

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Amitriptyline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Amivantamab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Amlodipine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Amodiaquine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Amoxicillin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Amphetamine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Amphetamine mixed salts

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Amphotericin B

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ampicillin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Anakinra

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Anastrozole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Anidulafungin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Antacids

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Anti-thymocyte globulin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Apalutamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Apixaban

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Apomorphine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Apremilast

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Aprepitant

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Argatroban

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Aripiprazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Artemether

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Artesunate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Asciminib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Asenapine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Aspirin (Analgesic)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Aspirin (Anti-platelet)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Atazanavir + ritonavir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Atazanavir alone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Atazanavir/cobicistat

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Atenolol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Atezolizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Atogepant

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Atomoxetine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Atorvastatin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Atovaquone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Atropine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Avanafil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Avapritinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Avatrombopag

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Avelumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Axitinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ayahuasca

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Azacitidine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Azathioprine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Azelastine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Azilsartan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Azithromycin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Baclofen

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Baloxavir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bamlanivimab/ Etesevimab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. Currently, limited data are available on the safety and effectiveness of COVID-19 vaccines in people who have received passive antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment or post-exposure prophylaxis. The American Centers for Disease Control and Prevention and the UK Health Security Agency both advise that vaccination should proceed without delay.

Description:

People who previously received antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment, post-exposure prophylaxis, or pre-exposure prophylaxis can be vaccinated at any time; COVID-19 vaccination does not need to be delayed following receipt of monoclonal antibodies or convalescent plasma. Although some reduction in vaccine-induced antibody titers was observed in people who previously received antibody products, the clinical significance of this reduction is unknown, and the balance of benefits vs. risks favors proceeding with vaccination even considering the possibility of diminished vaccine effectiveness in this situation.
Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Centers for Disease Control and Prevention, March 2022, https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.

Monoclonal antibodies to SARs-CoV-2 have recently been licensed for the treatment and prophylaxis of COVID-19 infection. Primate data suggests that administration of the AstraZeneca combination monoclonal antibody product did not interfere with the subsequent response to active vaccination. Based on this limited evidence, therefore, no specific interval is required between receipt of these products and COVID-19 vaccination, or vice versa.
COVID-19: the green book, chapter 14a. UK Health Security Agency, January 2022, www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a.

No Interaction Expected

COVID-19 vaccines

Baricitinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Basiliximab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bebtelovimab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. Currently, limited data are available on the safety and effectiveness of COVID-19 vaccines in people who have received passive antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment or post-exposure prophylaxis. The American Centers for Disease Control and Prevention and the UK Health Security Agency both advise that vaccination should proceed without delay.

Description:

People who previously received antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment, post-exposure prophylaxis, or pre-exposure prophylaxis can be vaccinated at any time; COVID-19 vaccination does not need to be delayed following receipt of monoclonal antibodies or convalescent plasma. Although some reduction in vaccine-induced antibody titers was observed in people who previously received antibody products, the clinical significance of this reduction is unknown, and the balance of benefits vs. risks favors proceeding with vaccination even considering the possibility of diminished vaccine effectiveness in this situation.
Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Centers for Disease Control and Prevention, March 2022, https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.

Monoclonal antibodies to SARs-CoV-2 have recently been licensed for the treatment and prophylaxis of COVID-19 infection. Primate data suggests that administration of the AstraZeneca combination monoclonal antibody product did not interfere with the subsequent response to active vaccination. Based on this limited evidence, therefore, no specific interval is required between receipt of these products and COVID-19 vaccination, or vice versa.
COVID-19: the green book, chapter 14a. UK Health Security Agency, January 2022, www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a.

No Interaction Expected

COVID-19 vaccines

Beclometasone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bedaquiline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Belatacept

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Belimumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bempedoic acid

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Benazepril

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bendamustine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bendroflumethiazide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Benralizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Benserazide/levodopa

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Benzatropine (Benztropine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Benzonatate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bepridil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Beta-alanine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Betahistine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Betamethasone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Betrixaban

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Bevacizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bexarotene

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bezafibrate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bicalutamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bictegravir/ Emtricitabine/ Tenofovir alafenamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Binimetinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Biperiden

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bisacodyl

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bismuth subsalicylate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bisoprolol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Blinatumomab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bortezomib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bosentan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bosutinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Branched chain amino acids (BCAAs; leucine, isoleucine, valine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Brentuximab vedotin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Brexpiprazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Brigatinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Brimonidine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Brincidofovir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Brinzolamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Brivaracetam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Brolucizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bromazepam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bromocriptine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Budesonide (inhaled)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Budesonide (oral/rectal)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bulevirtide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bumetanide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bupivacaine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Buprenorphine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Bupropion

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Buspirone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Butalbital

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cabazitaxel

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cabergoline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cabotegravir (oral)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cabotegravir/ rilpivirine (long acting)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cabozantinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Caffeine (anhydrous powder)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Calcium supplements

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Canagliflozin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Canakinumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Candesartan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cannabidiol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cannabis (Marijuana)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Capecitabine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Capmatinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Capreomycin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Captopril

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Carbamazepine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Carbidopa

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Carbidopa/levodopa

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Carbimazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Carbocisteine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Carboplatin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Carfentanil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely. However, carfentanil is an extremely strong opiate, reported to be up to 10,000 times more potent than morphine, and multiple deaths have resulted from its use. Advise patients to avoid.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Carfilzomib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cariprazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Carvedilol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Casirivimab/ Imdevimab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. Currently, limited data are available on the safety and effectiveness of COVID-19 vaccines in people who have received passive antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment or post-exposure prophylaxis. The American Centers for Disease Control and Prevention and the UK Health Security Agency both advise that vaccination should proceed without delay.

Description:

Casirivimab and imdevimab binds to epitopes on spike protein used as immunogen in all COVID-19 vaccines, therefore it is possible that casirivimab and imdevimab may interfere with the development of effective immune responses to COVID-19 vaccines. Refer to current vaccination guidelines with respect to timing of vaccination post treatment with anti-SARS-CoV-2 monoclonal antibodies. Limited safety data are available from the study HV-2093 where COVID-19 vaccine was permitted and no safety concerns were identified.
Ronapreve Summary of Product Characteristics, Roche Products Limited, August 2021.

People who previously received antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment, post-exposure prophylaxis, or pre-exposure prophylaxis can be vaccinated at any time; COVID-19 vaccination does not need to be delayed following receipt of monoclonal antibodies or convalescent plasma. Although some reduction in vaccine-induced antibody titers was observed in people who previously received antibody products, the clinical significance of this reduction is unknown, and the balance of benefits vs. risks favors proceeding with vaccination even considering the possibility of diminished vaccine effectiveness in this situation.
Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Centers for Disease Control and Prevention, March 2022, https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.

Monoclonal antibodies to SARs-CoV-2 have recently been licensed for the treatment and prophylaxis of COVID-19 infection. Primate data suggests that administration of the AstraZeneca combination monoclonal antibody product did not interfere with the subsequent response to active vaccination. Based on this limited evidence, therefore, no specific interval is required between receipt of these products and COVID-19 vaccination, or vice versa.
COVID-19: the green book, chapter 14a. UK Health Security Agency, January 2022, www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a.

No Interaction Expected

COVID-19 vaccines

Caspofungin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cat's Claw (Uncaria tomentosa)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cedazuridine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cefalexin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cefazolin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cefepime

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See summary)

No Interaction Expected

COVID-19 vaccines

Cefixime

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cefotaxime

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ceftazidime

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ceftriaxone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cefuroxime

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Celecoxib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cemiplimab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cenobamate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ceritinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Certolizumab pegol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cetirizine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cetuximab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Chlorambucil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Chloramphenicol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Chlordiazepoxide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Chloroquine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Chlorphenamine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Chlorpromazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Chlortalidone (Chlorthalidone)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ciclesonide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ciclosporin (Cyclosporine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cidofovir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cilazapril

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cilostazol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cimetidine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cinacalcet

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ciprofloxacin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cisapride

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cisatracurium

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Citalopram

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cladribine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. The ability to generate an immune response with COVID-19 vaccines under cladribine treatment has not been studied. However, a small study in patients with multiple sclerosis on anti-CD20 treatment suggest that COVID-19 vaccines may still provoke an appropriate immune response in those patients.

Description:

B cell and T cell responses to mRNA COVID-19 vaccination were studied in 20 patients taking anti-CD20 therapy for multiple sclerosis. A competent vaccine-induced CD8 T cell response was seen in these patients.
Sokratis A Apostolidis, Mihir Kakara, Mark M Painter et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy, Nature Medicine, 2021, 27:1990-2001.

No Interaction Expected

COVID-19 vaccines

Clarithromycin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Clavulanic acid

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Clindamycin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Clobazam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Clobetasol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Clofazimine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Clofibrate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Clomifene

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Clomipramine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Clonazepam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Clonidine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Clopidogrel

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Clopidogrel (recently stented patients)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Clorazepate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Clotrimazole (pessary, troche)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Clotrimazole (topical)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cloxacillin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Clozapine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cobimetinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cocaine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Codeine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Coenzyme Q10 (Ubidecarenone)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Colchicine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Colesevelam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Colestyramine (cholestyramine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Collagen hydrolysate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Conjugated estrogens (HRT)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

Potential Interaction

COVID-19 vaccines

Convalescent Plasma

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. Currently, limited data are available on the safety and effectiveness of COVID-19 vaccines in people who have received passive antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment or post-exposure prophylaxis. Although the American Centers for Disease Control and Prevention advises delaying COVID-19 vaccination for 30 days following passive antibody use for PEP and 90 days following treatment, the UK Health Security Agency indicates advises that no interval is required with monoclonal antibodies (but makes no mention of convalescent plasma). Please check local guidance.

Description:

Currently, there are limited data available on the safety and effectiveness of COVID-19 vaccines in people who received passive antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment or post-exposure prophylaxis. Based on the estimated half-life of such products and the anticipated period of protection against infection (when receiving anti-SARS-CoV-2 monoclonal antibodies for post-exposure prophylaxis) or reinfection (when receiving passive antibody therapy for treatment), COVID-19 vaccination should be temporarily deferred as a precautionary measure during the time period specified after receiving passive antibody products to avoid potential interference of the product with vaccine-induced immune responses. If the passive antibody product was used for post-exposure prophylaxis, defer COVID-19 vaccination for 30 days. If the passive antibody product was used for COVID-19 treatment, defer COVID-19 vaccination for 90 days.
Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States. Centers for Disease Control and Prevention, November 2021, www.cdc.gov/vaccines/covid-19/clinical-considerations.

Monoclonal antibodies to COVID-19 have recently been licensed for the treatment and prophylaxis of COVID-19 infection. Primate data suggests that administration of the AstraZeneca combination monoclonal antibody product did not interfere with the subsequent response to active vaccination. Based on this limited evidence, therefore, no specific interval is required between receipt of these products and COVID-19 vaccination, or vice versa.
COVID-19: the green book, chapter 14a. UK Health Security Agency, November 2021, www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a.

No Interaction Expected

COVID-19 vaccines

Creatine monohydrate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Crizanlizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Crizotinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cubeb pepper (Piper cubeba)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cyclizine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cyclobenzaprine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cyclophosphamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cycloserine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Cytisine (Cytisinicline)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dabigatran

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Dabrafenib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dacarbazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dacomitinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dactinomycin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dalteparin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Dantrolene sodium

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dapagliflozin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dapsone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Daratumumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Darifenacin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Darolutamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Darunavir + ritonavir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Darunavir/Cobicistat/ Emtricitabine/ Tenofovir alafenamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Darunavir/cobicistat

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dasatinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Decitabine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Deferasirox

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Delamanid

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Denosumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Desflurane

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Desipramine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Desloratadine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Desmopressin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Desogestrel (COC)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Desogestrel (POP)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Desvenlafaxine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dexamethasone (doses above 16 mg)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dexamethasone (low dose; 16 mg or less)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dexamfetamine (Dextroamphetamine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dexketoprofen

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dexlansoprazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dexmedetomidine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dexmethylphenidate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dextromethorphan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dextropropoxyphene

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Diamorphine (diacetylmorphine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Diazepam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Diclofenac

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dicycloverine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Difluprednate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Digoxin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dihydrocodeine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dihydroergotamine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Diltiazem

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dimethyl fumarate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Diphenhydramine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dipyridamole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Disopyramide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Disulfiram

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dobutamine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Docetaxel

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Docusate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dofetilide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dolasetron

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dolutegravir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dolutegravir/ Lamivudine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dolutegravir/ Rilpivirine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dolutegravir/Abacavir/ Lamivudine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Domperidone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Donepezil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dopamine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Doravirine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Doravirine/ Lamivudine/ Tenofovir-DF

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Doxazosin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Doxepin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Doxorubicin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Doxycycline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Doxylamine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dronabinol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dronedarone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Drospirenone (COC)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Drospirenone (HRT)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Drotaverine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dulaglutide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Duloxetine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dupilumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Durvalumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dutasteride

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Duvelisib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Dydrogesterone (HRT)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ecdysterone (20-hydroxyecdysone, 20E)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Echinacea

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ecstasy (MDMA)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Edoxaban

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Efavirenz

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Elbasvir/Grazoprevir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Eletriptan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Elotuzumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Eltrombopag

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Elvitegravir/Cobicistat/ Emtricitabine/ Tenofovir alafenamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Elvitegravir/Cobicistat/ Emtricitabine/ Tenofovir-DF

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Empagliflozin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Emtricitabine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Emtricitabine/ Tenofovir alafenamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Emtricitabine/ Tenofovir-DF

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Enalapril

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Enasidenib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Encorafenib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Enflurane

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Enfortumab vedotin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Enobosarm (Ostarine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Enoxaparin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Ensitrelvir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Entecavir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Enteral feeds

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Entrectinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Enzalutamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ephedrine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Epirubicin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Eplerenone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Epoprostenol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Eprosartan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Eptinezumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Erdafitinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Erenumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ergometrine (Ergonovine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ergotamine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Eribulin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Erlotinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ertapenem

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Erythromycin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Escitalopram

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Eslicarbazepine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Esomeprazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Estazolam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Estradiol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Eszopiclone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Etanercept

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ethambutol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ethinylestradiol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ethionamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ethosuximide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Etidocaine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Etonogestrel (implant)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Etonogestrel (vaginal ring)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Etoposide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Etoricoxib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Etravirine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Everolimus

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Evolocumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Exemestane

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Exenatide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ezetimibe

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Famciclovir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Famotidine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fampridine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Favipiravir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Febuxostat

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fedratinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Felodipine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fenofibrate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fentanyl

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ferrous fumarate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ferrous sulfate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fesoterodine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fexofenadine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fezolinetant

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Filgotinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Filgrastim

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Finasteride (1 mg)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Finasteride (5 mg)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Finerenone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fingolimod

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. The ability to generate an immune response with COVID-19 vaccines under fingolimod treatment has not been studied. However, a small study in patients with multiple sclerosis on anti-CD20 treatment suggest that COVID-19 vaccines may still provoke an appropriate immune response in those patients.

Description:

B cell and T cell responses to mRNA COVID-19 vaccination were studied in 20 patients taking anti-CD20 therapy for multiple sclerosis. A competent vaccine-induced CD8 T cell response was seen in these patients.
Sokratis A Apostolidis, Mihir Kakara, Mark M Painter et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy, Nature Medicine, 2021, 27:1990-2001.

No Interaction Expected

COVID-19 vaccines

Fish oils

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Flecainide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Flibanserin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Flucloxacillin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fluconazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Flucytosine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fludrocortisone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Flunisolide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Flunitrazepam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fluocinolone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fluorouracil (5-FU)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fluoxetine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Flupentixol (Flupenthixol)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fluphenazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Flurazepam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Flutamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fluticasone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fluvastatin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fluvoxamine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Folic acid

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fondaparinux

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution ton individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Formoterol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Foscarnet

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fosfomycin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fosinopril

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fostamatinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fostemsavir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fremanuzemab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Frovatriptan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fulvestrant

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Furosemide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fusidic acid (oral or IV)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Fusidic acid (topical)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

GHB (Gamma-hydroxybutyrate)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Gabapentin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Galantamine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Galcanezumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ganciclovir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Garlic

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Gefitinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Gemcitabine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Gemfibrozil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Gentamicin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Gestodene (COC)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Gilteritinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ginger (Zingiber officinale)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ginkgo biloba

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ginseng (Panax ginseng, Panax quinquefolis)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Glasdegib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Glatiramer acetate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Glecaprevir/Pibrentasvir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Glibenclamide (Glyburide)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Gliclazide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Glimepiride

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Glipizide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Glucosamine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Glyceryl trinitrate (Nitroglycerin)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Glycopyrronium bromide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Golimumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Goserelin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Granisetron

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Grapefruit juice

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Griseofulvin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Guaifenesin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Guanfacine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Guggulsterone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Halofantrine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Haloperidol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Halothane

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Heparin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Heroin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Homeopathic remedies

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely. There is no evidence that homeopathic remedies interact with conventional medicines, provided they are from a reputable source, and of the strength stated. However, caution may be required as some remedies termed “low

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Hops (Humulus lupulus)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Hydralazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Hydrochlorothiazide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Hydrocodone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Hydrocortisone (oral or IV)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Hydrocortisone (topical)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Hydromorphone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Hydroxycarbamide (Hydroxyurea)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Hydroxychloroquine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Hydroxyzine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Hyoscine (Scopolamine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Hyoscine butylbromide (Butylscopolamine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Hyoscine hydrobromide (Scopolamine hydrobromide)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ibalizumab-uiyk

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ibandronic acid (Ibandronate)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely. Of note, ibandronic acid is contraindicated in patients unable stand or sit upright for at least 60 minutes.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ibrutinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ibuprofen

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Icosapent ethyl

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Idelalisib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Iloperidone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Iloprost

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Imatinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Imatinib (14 days for COVID-19)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Imipenem/Cilastatin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Imipramine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Inclisiran

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Indacaterol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Indapamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Indometacin (Indomethacin)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Infigratinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

Potential Interaction

COVID-19 vaccines

Infliximab

Quality of Evidence: Low

Summary:

Anti-SARS-CoV-2 antibody concentrations were shown to be lower in patients treated with infliximab following a single vaccination dose with the BNT162b2 (Pfizer) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca) SARS-CoV-2 vaccines. Vaccination after SARS-CoV-2 infection, or a second dose of vaccine, led to seroconversion in most patients. Delayed second dosing should be avoided in patients treated with infliximab.

Description:

This study investigated whether patients with inflammatory bowel disease treated with infliximab had attenuated serological responses to a single dose of a SARS-CoV-2 vaccine. Antibody responses and seroconversion rates in infliximab-treated patients (n=865) were compared with a cohort treated with vedolizumab (n=428), a gut-selective anti-integrin α4β7 monoclonal antibody. The primary outcome was anti-SARS-CoV-2 spike (S) antibody concentrations 3-10 weeks after vaccination, in patients without evidence of prior infection. Infliximab is associated with attenuated immunogenicity to a single dose of the BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. Geometric mean (SD) anti-SARS-CoV-2 antibody concentrations were lower in patients treated with infliximab than vedolizumab, following BNT162b2 (6.0 U/mL (5.9) vs 28.8 U/mL (5.4) p<0.0001) and ChAdOx1 nCoV-19 (4.7 U/mL (4.9)) vs 13.8 U/mL (5.9) p<0.0001) vaccines. Vaccination after SARS-CoV-2 infection, or a second dose of vaccine, led to seroconversion in most patients. Delayed second dosing should be avoided in patients treated with infliximab.
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Kennedy NA, Lin S, Goodhand JR, et al. Gut. 2021; 70(10):1884-1893.

No Interaction Expected

COVID-19 vaccines

Inotuzumab ozogamicin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Insulin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Interferon beta

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Iodine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ipilimumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ipratropium bromide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Irbesartan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Irinotecan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Iron supplements

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Isavuconazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Isoflurane

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Isoniazid

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Isosorbide dinitrate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Isosorbide mononitrate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Isotretinoin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ispaghula husk

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Itraconazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ivabradine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ivacaftor

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ivacaftor/lumacaftor

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ivacaftor/tezacaftor

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ivacaftor/tezacaftor/elexacaftor

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ivermectin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ivosidenib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ixazomib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ixekizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Kanamycin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ketamine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ketoconazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ketoprofen

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ketorolac

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

LSD (Lysergic acid diethylamide)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Labetalol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lacidipine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lacosamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lactulose

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lamivudine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lamotrigine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lansoprazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lapatinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Larotrectinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Latanoprost

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ledipasvir/Sofosbuvir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Leflunomide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lenacapavir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lenalidomide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lenvatinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lercanidipine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Letermovir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Letrozole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Leuprorelin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Levetiracetam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Levocetirizine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Levodopa

Quality of Evidence: Very Low

Summary:

Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. In the presence of a peripheral dopa-decarboxylase inhibitor (carbidopa or benserazide) levodopa is metabolised mainly to 3-O-methyldopa by catechol-O-methyltransferase.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Levofloxacin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Levomepromazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Levonorgestrel (COC)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Levonorgestrel (Emergency Contraception)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Levonorgestrel (HRT)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Levonorgestrel (IUD)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Levonorgestrel (POP)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Levonorgestrel (implant)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Levothyroxine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lidocaine (Lignocaine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Linaclotide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Linagliptin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Linezolid

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Liothyronine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Liquorice (Glycyrrhiza glabra)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Liraglutide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lisdexamfetamine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lisinopril

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lithium

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lomitapide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lomustine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Loperamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lopinavir/ritonavir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Loratadine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lorazepam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lorlatinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lormetazepam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Losartan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lovastatin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lumateperone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lumefantrine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lurasidone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Lymecycline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Macitentan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Macrogol (Polyethylene glycol, PEG 3350, PEG 4000)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Magnesium salts (oral)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Magnesium sulfate (IV)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Malabar nut tree (Justicia adhatoda, Adhatoda vasica)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Maprotiline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Maraviroc

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Maribavir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mebeverine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Meclizine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Medroxyprogesterone (depot injection)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Medroxyprogesterone (oral)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mefenamic acid

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mefloquine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Megestrol acetate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Melatonin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Meloxicam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Memantine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mepolizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mercaptopurine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Meropenem

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mesalazine (mesalamine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Metamizole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Metformin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Methadone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Methamphetamine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Methimazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Methocarbamol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Methotrexate (cancer therapy)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Methotrexate (immunosuppressant)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Methyldopa

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Methylergometrine (Methylergonovine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Methylphenidate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Methylprednisolone (oral or IV)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Methylprednisolone (topical)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Metoclopramide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Metolazone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Metoprolol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Metronidazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mexiletine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mianserin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Micafungin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Miconazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Midazolam (buccal)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Midazolam (oral)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Midazolam (parenteral)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Midodrine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Midostaurin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Milk thistle (Silybum marianum, Silymarin)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Milnacipran

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Minocycline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Minoxidil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mirabegron

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mirtazapine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Misoprostol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mitomycin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mitotane

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mobocertinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Moclobemide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Modafinil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Molnupiravir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mometasone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Montelukast

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Morphine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Moxifloxacin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Moxonidine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Multivitamins

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Mycophenolate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nabumetone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Naftidrofuryl

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Naloxegol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Naloxone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Naltrexone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nandrolone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Naproxen

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Naratriptan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Natalizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nateglinide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nebivolol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Necitumumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nefazodone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nefopam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Neostigmine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Neratinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Netupitant

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nevirapine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nicardipine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Niclosamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nicorandil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nicotinamide (Niacinamide)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nicotine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nifedipine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nilotinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nimesulide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nintedanib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Niraparib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nirmatrelvir/ritonavir (5 days)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nirmatrelvir/ritonavir (extended administration; 10 days or longer)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nisoldipine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nitazenes

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nitazoxanide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nitrendipine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nitrofurantoin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nitrous oxide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nivolumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nizatidine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Noradrenaline (Norepinephrine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Norelgestromin (patch)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Norethisterone [Norethindrone] (COC)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Norethisterone [Norethindrone] (HRT)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Norethisterone [Norethindrone] (IM depot injection)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Norethisterone [Norethindrone] (POP)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Norgestimate (COC)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Norgestrel (COC)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Norgestrel (HRT)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nortriptyline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Nystatin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Obinutuzumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ocrelizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Octreotide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ofatumumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ofloxacin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Olanzapine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Olaparib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Olaratumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Olmesartan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Olodaterol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Omalizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ombitasvir/Paritaprevir/r

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ombitasvir/Paritaprevir/r + Dasabuvir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Omega-3 fatty acids

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Omeprazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ondansetron

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Opipramol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Oral nutritional supplements

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Orlistat

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Orphenadrine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Oseltamivir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Osimertinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ospemifene

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Oxaliplatin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Oxandrolone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Oxazepam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Oxcarbazepine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Oxprenolol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Oxybutynin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Oxycodone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Oxymetholone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ozanimod

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely. The ability to generate an immune response with COVID-19 vaccines under ozanimod treatment has not been studied. However, a small study in patients with multiple sclerosis on anti-CD20 treatment suggest that COVID-19 vaccines may still provoke an appropriate immune response in those patients.

Description:

B cell and T cell responses to mRNA COVID-19 vaccination were studied in 20 patients taking anti-CD20 therapy for multiple sclerosis. A competent vaccine-induced CD8 T cell response was seen in these patients.
Sokratis A Apostolidis, Mihir Kakara, Mark M Painter et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy, Nature Medicine, 2021, 27:1990-2001.

No Interaction Expected

COVID-19 vaccines

Paclitaxel

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Palbociclib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Paliperidone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Palonosetron

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pancreatic enzymes (Creon)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Panitumumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Panobinostat

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pantoprazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Para-aminosalicylic acid

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Paracetamol (Acetaminophen)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Paroxetine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pazopanib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Peginterferon beta-1a

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pembrolizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pemetrexed

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pemigatinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Penicillins

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pentoxifylline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Perampanel

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Perazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Periciazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Perindopril

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Perphenazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pertuzumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pethidine (Meperidine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pexidartinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Phenelzine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Phenobarbital (Phenobarbitone)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Phenprocoumon

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Phentermine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Phenylephrine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Phenytoin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pilocarpine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pimavanserin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pimozide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pindolol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pioglitazone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Piperacillin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Piperaquine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pipotiazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pirfenidone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Piribedil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Piroxicam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pitavastatin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pitolisant

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pizotifen

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Polatuzumab vedotin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pomalidomide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ponatinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Poppers (Amyl nitrate)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Posaconazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Potassium

Quality of Evidence: Very Low

Summary:

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as potassium is eliminated renally.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pralsetinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pramipexole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Prasugrel

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution ito individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Pravastatin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Prazosin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Prednisolone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Prednisone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pregabalin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Primaquine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Primidone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Probenecid

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Prochlorperazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Procyclidine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Progesterone (HRT)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Proguanil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Promethazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Propafenone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Propofol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Propranolol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Propylthiouracil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Prucalopride

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pseudoephedrine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Psilocybin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Psyllium husk

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pyrazinamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pyridostigmine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Pyrimethamine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Quercetin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Quetiapine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Quinapril

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Quinidine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Quinine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rabeprazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Raloxifene

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Raltegravir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ramipril

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ranibizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ranitidine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ranolazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rasagiline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Reboxetine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Red yeast rice

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Regorafenib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Relugolix

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Remdesivir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Remifentanil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Repaglinide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Retigabine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ribavirin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ribociclib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rifabutin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rifampicin (Rifampin)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rifapentine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rifaximin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rilpivirine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rilpivirine/ Emtricitabine/ Tenofovir alafenamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rilpivirine/ Emtricitabine/ Tenofovir-DF

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Riluzole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rimantadine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rimegepant

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Riociguat

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ripretinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Risankizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Risedronic acid (Risedronate)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Risperidone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rituximab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rivaroxaban

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Rivastigmine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rizatriptan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rocuronium

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Roflumilast

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ropinirole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rosiglitazone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rosuvastatin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rotigotine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rucaparib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Rufinamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ruxolitinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sacubitril

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Safinamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Salbutamol (Albuterol)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Salmeterol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sarilumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Saxagliptin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Secukinumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Selexipag

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Selinexor

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Selpercatinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Semaglutide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Senna

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sertraline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sevelamer

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sevoflurane

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sildenafil (Erectile Dysfunction)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sildenafil (Pulmonary Arterial Hypertension)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Silodosin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Simvastatin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Siponimod

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. The ability to generate an immune response with COVID-19 vaccines under siponimod treatment has not been studied. However, a small study in patients with multiple sclerosis on anti-CD20 treatment suggest that COVID-19 vaccines may still provoke an appropriate immune response in those patients.

Description:

B cell and T cell responses to mRNA COVID-19 vaccination were studied in 20 patients taking anti-CD20 therapy for multiple sclerosis. A competent vaccine-induced CD8 T cell response was seen in these patients.
Sokratis A Apostolidis, Mihir Kakara, Mark M Painter et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy, Nature Medicine, 2021, 27:1990-2001.

No Interaction Expected

COVID-19 vaccines

Sirolimus

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sitagliptin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sodium nitroprusside

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sodium valproate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sofosbuvir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sofosbuvir/Velpatasvir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sofosbuvir/Velpatasvir/Voxilaprevir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Solifenacin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sonidegib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sorafenib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sotalol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sotorasib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sotrovimab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. Currently, limited data are available on the safety and effectiveness of COVID-19 vaccines in people who have received passive antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment or post-exposure prophylaxis. The American Centers for Disease Control and Prevention and the UK Health Security Agency both advise that vaccination should proceed without delay.

Description:

People who previously received antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment, post-exposure prophylaxis, or pre-exposure prophylaxis can be vaccinated at any time; COVID-19 vaccination does not need to be delayed following receipt of monoclonal antibodies or convalescent plasma. Although some reduction in vaccine-induced antibody titers was observed in people who previously received antibody products, the clinical significance of this reduction is unknown, and the balance of benefits vs. risks favors proceeding with vaccination even considering the possibility of diminished vaccine effectiveness in this situation.
Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Centers for Disease Control and Prevention, March 2022, https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.

Monoclonal antibodies to SARs-CoV-2 have recently been licensed for the treatment and prophylaxis of COVID-19 infection. Primate data suggests that administration of the AstraZeneca combination monoclonal antibody product did not interfere with the subsequent response to active vaccination. Based on this limited evidence, therefore, no specific interval is required between receipt of these products and COVID-19 vaccination, or vice versa.
COVID-19: the green book, chapter 14a. UK Health Security Agency, January 2022, www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a.

No Interaction Expected

COVID-19 vaccines

Spectinomycin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Spironolactone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

St John's Wort

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Stanozolol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Streptokinase

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Streptomycin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, 2020.

Individuals on stable anticoagulation therapy, including individuals on warfarin who are up-to-date with their scheduled INR testing and whose latest INR is below the upper level of the therapeutic range, can receive intramuscular vaccination.
The Green Book, Chapter 14a - COVID-10 - SARS-CoV-2, December 2020.

No Interaction Expected

COVID-19 vaccines

Sucralfate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sufentanil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sulfadiazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sulfadoxine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sulfasalazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sulpiride

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sultiame

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sumatriptan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Sunitinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Suvorexant

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Suxamethonium (Succinylcholine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tacrolimus

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tadalafil (BPH)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tadalafil (Erectile Dysfunction)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tadalafil (Pulmonary Arterial Hypertension)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Talazoparib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tamoxifen

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tamsulosin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tapentadol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tazobactam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tecovirimat

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tegafur/ Gimeracil/ Oteracil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Teicoplanin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Telbivudine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Telithromycin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Telmisartan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Temazepam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Temsirolimus

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tenapanor

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tenofovir alafenamide (HBV)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tenofovir-DF

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tepotinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Terazosin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Terbinafine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Terbutaline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Teriflunomide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Testosterone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tetracaine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tetracyclines

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Thalidomide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Theophylline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Thiopental

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Thioridazine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tiagabine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tiapride

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ticagrelor

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Ticlopidine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Timolol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tinidazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tinzaparin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Tiotropium bromide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tirzepatide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tisotumab vedotin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tivozanib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

Potential Interaction

COVID-19 vaccines

Tixagevimab/ Cilgavimab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. Currently, limited data are available on the safety and effectiveness of COVID-19 vaccines in people who have received passive antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment or post-exposure prophylaxis. The American Centers for Disease Control and Prevention and the UK Health Security Agency both advise that vaccination should proceed without delay after administration of monoclonal antibodies. However, the CDC advises that tixagevimab/cilgavimab used for pre-exposure prophylaxis (PrEP) should be administered at least two weeks after vaccination. Check local guidelines.

Description:

In individuals who have received a COVID-19 vaccine, EVUSHELD should be administered at least two weeks after vaccination.
Fact Sheet for Healthcare Providers: Emergency Use Authorization for Evusheld, AstraZeneca, April 2022.

People who previously received antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment, post-exposure prophylaxis, or pre-exposure prophylaxis can be vaccinated at any time; COVID-19 vaccination does not need to be delayed following receipt of monoclonal antibodies or convalescent plasma. Although some reduction in vaccine-induced antibody titers was observed in people who previously received antibody products, the clinical significance of this reduction is unknown, and the balance of benefits vs. risks favors proceeding with vaccination even considering the possibility of diminished vaccine effectiveness in this situation. However, in people who previously received a COVID-19 vaccine, administration of tixagevimab/cilgavimab (EVUSHELD™) for pre-exposure prophylaxis should be deferred for at least two weeks after vaccination, per the product EUA.
Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Centers for Disease Control and Prevention, March 2022, https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.

Monoclonal antibodies to SARs-CoV-2 have recently been licensed for the treatment and prophylaxis of COVID-19 infection. Primate data suggests that administration of the AstraZeneca combination monoclonal antibody product did not interfere with the subsequent response to active vaccination. Based on this limited evidence, therefore, no specific interval is required between receipt of these products and COVID-19 vaccination, or vice versa.
COVID-19: the green book, chapter 14a. UK Health Security Agency, January 2022, www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a.

No Interaction Expected

COVID-19 vaccines

Tizanidine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tocilizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tofacitinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tolbutamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tolterodine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tolvaptan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Topiramate

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Topotecan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Torasemide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Toremifene

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tramadol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Trametinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Trandolapril

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tranexamic acid

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Tranylcypromine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Trastuzumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Trastuzumab emtansine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Travoprost

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Trazodone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Trenbolone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Treprostinil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Triamcinolone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Triamterene

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Triazolam

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Triclabendazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Trifluridine/Tipiracil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Trimethoprim/Sulfamethoxazole (Co-trimoxazole)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Trimipramine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Triptorelin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Trospium

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Turmeric (Curcumin)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ubrogepant

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ulipristal

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Umbralisib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Umeclidinium bromide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Upadacitinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ursodeoxycholic acid (Ursodiol)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ustekinumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely. A clinical trial found no difference in anti-SARS-CoV-2 spike protein antibody concentrations between patients with IBD treated with ustekinumab and healthy controls.

Description:

Anti-SARS-CoV-2 spike protein antibody concentration after 2 doses of COVID-19 vaccine in IBD patients was studied in a multi-centre, prospective, case-control study. Patients on ustekinumab did not have significantly different antibody concentrations to healthy controls (n=57, 582.5 U/mL, p=0.11). Vaccinations included ChAdOx1 nCoV-19, BNT162b2, or mRNA1273 [Moderna].
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. J L Alexander, N A Kennedy, H Ibraheim et al. Lancet Gastroenterol Hepatol. 2022;7(4):342-352.

No Interaction Expected

COVID-19 vaccines

Valaciclovir (Valacyclovir)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Valerian

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Valganciclovir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Valproate semisodium (Divalproex sodium)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Valproic acid

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Valsartan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vancomycin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vandetanib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vardenafil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Varenicline

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vasopressin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vecuronium

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vedolizumab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely. A clinical trial found no difference in anti-SARS-CoV-2 spike protein antibody concentrations between patients with IBD treated with vedolizumab and healthy controls.

Description:

Anti-SARS-CoV-2 spike protein antibody concentration after 2 doses of COVID-19 vaccine in IBD patients was studied in a multi-centre, prospective, case-control study. Patients on vedolizumab did not have significantly different antibody concentrations to healthy controls (n=62, 954 U/mL, p=0.5). Vaccinations included ChAdOx1 nCoV-19, BNT162b2, or mRNA1273 [Moderna].
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. J L Alexander, N A Kennedy, H Ibraheim et al. Lancet Gastroenterol Hepatol. 2022;7(4):342-352.

No Interaction Expected

COVID-19 vaccines

Vemurafenib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Venetoclax

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Venlafaxine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Verapamil

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vigabatrin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vilanterol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vilazodone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vildagliptin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vilobelimab

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vinblastine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vincristine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vinorelbine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vitamin A (Retinol)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vitamin B1 (Thiamine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vitamin B12 (Cyanocobalamin)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vitamin B2 (Riboflavin)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vitamin B3 (Niacin, nicotinic acid)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vitamin B6 (Pyridoxine)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vitamin B7 (Biotin)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vitamin C (Ascorbic Acid)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vitamin D2 (Ergocalciferol)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vitamin D3 (Colecalciferol, cholecalciferol)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vitamin E (Tocopherol)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vitamin K (Phytomenadione)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Voclosporin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vorapaxar

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Voriconazole

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Vortioxetine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Warfarin

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a pharmacokinetic interaction is considered unlikely. As with other intramuscular injections, COVID-19 vaccines should be given with caution to individuals receiving anticoagulant therapy as bleeding or bruising may occur following an intramuscular injection in these individuals.

Description:

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
Comirnaty European Summary of Product Characteristics, Pfizer/BioNTech, January 2021.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
COVID-19 mRNA Vaccine European Summary of Product Characteristics, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, REG 174 Information for UK Healthcare Professionals, Pfizer/BioNTech, December 2020.

As with other intramuscular injections, COVID-19 Vaccine Moderna should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma following the injection.
COVID-19 Vaccine Moderna dispersion for injection, REG 174 Information for UK Healthcare Professionals, Moderna, January 2021.

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection, should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.
COVID-19 Vaccine Astra/Zeneca solution for injection, REG 174 Information for UK Healthcare Professionals, AstraZeneca, December 2020.

No Interaction Expected

COVID-19 vaccines

Whey protein

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Xipamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Zaleplon

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Zanamivir

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Zanubrutinib

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Zidovudine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Zinc

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Ziprasidone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Zoledronic acid (Zoledronate)

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Zolmitriptan

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Zolpidem

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Zonisamide

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Zopiclone

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Zotepine

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

No Interaction Expected

COVID-19 vaccines

Zuclopenthixol

Quality of Evidence: Very Low

Summary:

Coadministration has not been formally studied but based on current knowledge of the effect of vaccines on drug disposition a clinically significant interaction is considered unlikely.

Description:

(See Summary)

Academic Sponsors / Collaborators
Editorial Sponsors / Research Funders
Cookie Policy Privacy Statement Terms & Conditions

Copyright © 2024 The University of Liverpool. All rights reserved.